*Event date: 2026-09-02*

A drug first approved in the United States for metastatic pancreatic cancer is now showing an early signal in lung cancer, according to clinical trial results reported in the New England Journal of Medicine and summarized by NBC News. In the study, about one-third of patients with advanced lung cancer saw their tumors shrink after receiving daraxonrasib, a RAS inhibitor that had already drawn attention for its use in pancreatic disease.

The result is notable because the drug is being tested against the most common form of lung cancer, a disease that remains one of the hardest to treat once it has spread. The NBC News report said the trial was early and that larger studies are underway, which means the findings are promising but still preliminary. The current evidence is enough to justify closer research, but not enough to support any claim that daraxonrasib has become a proven lung cancer treatment.

The report does not give the full trial design, patient count or duration of response in the excerpted material, so those details should not be inferred. What can be said from the supplied evidence is narrower and more important: researchers have now observed measurable tumor shrinkage in a meaningful subset of advanced lung cancer patients, and they are continuing with bigger trials to learn whether that effect holds up in broader use.

That distinction matters because early oncology signals often look stronger before they are tested at scale. Tumor shrinkage can indicate that a drug is hitting its target, but longer follow-up is needed to understand whether it improves survival, delays progression or produces side effects that offset the benefit. The fact that the study was published in a top medical journal adds weight to the result, but publication alone does not settle how the drug will fit into routine care.

Daraxonrasib’s original approval for metastatic pancreatic cancer also frames the result as part of a broader push to use RAS-pathway drugs against several tumor types. The same biology that makes pancreatic cancer difficult to treat can also appear in other cancers, which is why a signal in lung cancer is attracting attention. Still, the leap from one indication to another is substantial. A drug can work in one cancer and fail in another even when the underlying molecular target is related.

For patients and clinicians, the immediate takeaway is one of cautious optimism. The evidence in hand suggests that a recently approved cancer drug is being actively repurposed and that the first signs in lung cancer are encouraging. It does not yet justify changing standard treatment outside a trial setting, and it does not remove the need for larger, confirmatory studies.

If those studies reproduce the early shrinkage seen so far, daraxonrasib could become more than a pancreatic cancer therapy and move toward a broader role in oncology. For now, the story is best understood as an early but credible research signal: a new drug with one approval already in hand has now shown enough activity in advanced lung cancer to keep investigators moving forward.

The next readout will matter because it will tell researchers whether this was a useful first step or the start of a much larger treatment story.